Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.

Abstract

This study evaluated the safety and efficacy of combined treatment with epsilon-aminocaproic acid or tranexamic acid and monoclonal antibody purified factor IX (MAb factor IX) for prophylaxis against bleeding in eight hemophilia B patients undergoing nine dental extraction procedures. All patients achieved excellent hemostasis without clinical evidence of thrombosis. There were no significant changes in hemoglobin or hematocrit or in markers of hemostatic system activation (prothrombin fragment F1+2, fibrinopeptide A, and fragment B beta 15-42) after surgery. Thus, a highly purified factor IX concentrate and antifibrinolytic therapy can be effectively and safely combined in hemophilia B patients undergoing dental extractions.

• Authors: B Djulbegovic, M Marasa, A Pesto, G M Kushner, T Hadley, G Joseph, G Goldsmith
• Journal: American journal of hematology (Am J Hematol) Vol. 51 Issue 2 Pg. 168-70 (Feb 1996) ISSN: 0361-8609 [Print] United States
• PMID: 8579061 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antifibrinolytic Agents
• Factor IX
• Aminocaproic Acid

Topics

• Adult
• Aminocaproic Acid (therapeutic use)
• Antifibrinolytic Agents (therapeutic use)
• Factor IX (therapeutic use)
• Hemophilia B (therapy)
• Hemorrhage (prevention & control)
• Humans
• Middle Aged
• Prospective Studies
• Tooth Extraction (adverse effects)